ReviewExperimental & molecular medicine2020
Gastrointestinal tract modeling using organoids engineered with cellular and microbiota niches.
Review in Experimental & molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Pooled it
- The sixth sense of the brain: interoception in organoid study.Bone research · 2026Review
- Discovery and characterization of a hydroxypyridone-3-carboxamide analog as an antiviral lead against orthopoxviruses.Antimicrobial agents and chemotherapy · 2026Article
- Patient-Derived Organoids in Gastrointestinal Disease: Current Applications, Limitations, and Future Perspectives.International journal of molecular sciences · 2026Review
- Breaking the Barrier: Pro-inflammatory Stool from Infants with CHD Triggers Barrier Dysfunction within Intestinal Organoids.Research square · 2026Article
- Intestinal Barrier Dysfunction and Stem Cell Impairment Following Cardiac Surgery in Pigs: A Porcine Model Study.Biology · 2026Article
- Gut microbiota-M cell co-culture in inflammatory bowel disease and its therapeutic potential in organoid platforms.Frontiers in pharmacology · 2026Review
- Organoid models: applications and research advances in gastric cancer.Frontiers in oncology · 2026Review
- Gastric bacterial microbiota and gastric carcinogenesis: from dysbiosis to immune remodeling and therapeutic opportunities.Frontiers in immunology · 2026Review
- Microbial metabolite-mediated modulation of enteroendocrine and immune pathways byFrontiers in endocrinology · 2026Article
- Discovery and Characterization of a Hydroxypyridone-3-carboxamide Analog as an Antiviral Lead against Orthopoxviruses.bioRxiv : the preprint server for biology · 2025Article
- Next-Generation Therapies for Gastrointestinal Repair: Converging Traditional Medicine and Tissue Engineering.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Immune and Immune-Integrated Organoids as NextGeneration Platforms for Disease Modeling.MedComm · 2025Review
- Gastric Cancer Treatment New Chapter: Organoid Models Leading Personalized Medicine.Molecular diagnosis & therapy · 2025Review
- In Vitro and Ex Vivo Models to Study Molecular Trafficking Across the Human Intestinal Barrier.International journal of molecular sciences · 2025Review
- Advances and applications of gut organoids: modeling intestinal diseases and therapeutic development.Life medicine · 2025Review
- Glycaemic sugar metabolism and the gut microbiota: past, present and future.The FEBS journal · 2025Review
- AI-driven multi-omics profiling of sepsis immunity in the digestive system.Frontiers in immunology · 2025Review
- Developments in gastrointestinal organoid cultures to recapitulate tissue environments.Frontiers in bioengineering and biotechnology · 2025Review
- Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent emergence of organoid technology has attracted great attention in gastroenterology because the gastrointestinal (GI) tract can be recapitulated in vitro using organoids, enabling disease modeling and mechanistic studies. However, to more precisely emulate the GI microenvironment in vivo, several neighboring cell types and types of microbiota need to be integrated into GI organoids. This article reviews the recent progress made in elucidating the crosstalk between GI organoids and components of their microenvironment. We outline the effects of stromal cells (such as fibroblasts, neural cells, immune cells, and vascular cells) on the gastric and intestinal epithelia of organoids. Because of the important roles that microbiota play in the physiology and function of the GI tract, we also highlight interactions between organoids and commensal, symbiotic, and pathogenic microorganisms and viruses. GI organoid models that contain niche components will provide new insight into gastroenterological pathophysiology and disease mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.